Expert Interviews

The expert in breast imaging spoke about the latest in breast imaging and the new technologies that are helping to advance the field.

The expert in breast imaging spoke about the use of the technology, and why it is more effective than traditional mammograms.

New research from NCI-MATCH support the feasibility and efficiency of using next-generation sequencing (NGS) to triage patients to investigational therapy, given that a sufficiently large pool of agents is provided.

The breast cancer expert discussed the changes he has made in treating this patient population as a result of the COVID-19 pandemic.

New research reported that guidelines to reduce the number of opioids prescribed to patients following surgery may be missing a small group of patients that need a greater level of pain control.

Among accredited US cancer centers, hospitals which serve primarily minority patients were found to be as likely as other hospitals to offer the standard of surgical care for early-stage breast cancer.

Research suggested that limited English-language proficiency is a risk factor for getting potentially lifesaving screening mammograms less often.

Researchers found that patients who participated in virtual follow-up visits benefitted by spending less time waiting at and traveling to the clinic for in-person appointments.

Moss indicated that “we need interventions in these communities to change cancer-causing behaviors, to make cancer screening more accessible, to improve treatment, and to promote quality of life and survivorship.”

The expert from the Otto J. Ruesch Center for the Cure of Gastrointestinal Cancers discussed precision medicine with regard to cancer care, as well as the need to make such care more accessible for the global community.

The findings from this study are intended to inform the Curriculum for Oncologists on LGBTQ+ populations to Optimize Relevance and Skills (COLORS) Training Program.

According to researchers, a “better understanding of the heterogeneity of mCRC, including primary tumor location, microsatellite instability (MSI) status, and other clinically actionable tumor mutations, is reshaping the therapeutic landscape.”